Weight-Loss drug may ease skin disease in overweight patients
NCT ID NCT07401992
Summary
This study is testing if adding the oral medication semaglutide to standard psoriasis skin cream can better control the skin disease in people who are also overweight or have type 2 diabetes. Researchers will enroll 62 participants to receive either semaglutide or a placebo pill, along with the skin cream, for 12 weeks. The main goal is to see if the drug improves skin symptoms and reduces body-wide inflammation more than the placebo.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DIABETES MELLITUS, TYPE 2 are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Hospital Universitario Dr. José E. González
RECRUITINGMonterrey, N.L., 64460, Mexico
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.